Publications — Other

There is active research around YKL-40 as a biomarker in a variety of disease states.  Recent studies have linked elevated YKL-40 levels to a variety of aggressive and invasive cancers, asthma and cirrhosis.  A list of publications can be found in the links at the right.

1. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM, Hellerbrand C, Mueller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009; 50(2):370-376.
2. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009; 7:219-226.
3. Zheng JL, Lu L, Hu J, Zhang RY, Zhang Q, Chen QJ, Shen WF. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis. 2009; 210(2):590-595.
4. Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8-61. Review.
5. Hempen M, Kopp HP, Elhenicky M, Höbaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg. 2009;19(11):1557-63.
6. Hattori N, Oda S, Sadahiro T, Nakamura M, Abe R, Shinozaki K, Nomura F, Tomonaga T, Matsushita K, Kodera Y, Sogawa K, Satoh M, Hirasawa H. YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock. 2009;32(4):393-400.
7. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32(2):323-8.
8. Seol H. Serum levels of YKL-40 and interleukin-18 and their relationship to disease severity in patients with preeclampsia. J Repro Immunol. 2009: 79(2):183-187.
9. Johansen JS, Bojesen SE, Tybjaerg-Hansen A, Mylin AK, Price PA, Nordestgaard BG. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem. 2010: 56(10):1580-1591.
10. Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sørensen K, Klingvall MF, Brosstad F, Oie E, Vestergaard H, Aukrust P, Halvorsen B. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis. 2010 Mar 4.
11. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, Silva AE. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol. 2010 ;45(5):615-22
12. Masajtis-Zagajewska A, Majer J, Nowicki M. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. Hypertens Res. 2010 ;33(4):348-53
13. Hedegaard A, Sejersten Ripa R, Johansen JS, Jørgensen E, Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest. 2010 ;70(2):80-6.
14. Andreassen M, Raymond I, Hildebrandt P, Kistorp C, Rathcke C, Vestergaard H, Faber J, Kristensen LO. Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population. Inflamm Res. 2010 Jan 3.
15. Henningsen KM, Nilsson B, Johansen JS, Chen X, Pehrson S, Svendsen JH. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res. 2010;59(6):463-9.
16. Rathcke CN, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Lip GY, Faber J, Vestergaard H. Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand Cardiovasc J. 2010; 44(2):92-9.
17. Rego-Pérez I, Fernández-Moreno M, Deberg M, Pértega S, Fenández-López C, Oreiro N, Henrotin Y, Blanco FJ. Mitochondrial DNA haplogroups modulate the serum levels of biomarkers in patients with osteoarthritis. Ann Rheum Dis. 2010; 69(5):910-7.
18. Lee KG, Seo YS, An H, Um SH, Jung ES, Keum B, Yim HJ, Jeen YT, Chun HJ, Kim CD, Ryu HS. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25(1):94-100.
19. Kim PJ, Hong DG, Park JY, Cho YL, Park IS, Lee YS. Immunohistochemical expression of YKL-40 in peritoneal endometriosis. Gynecol Endocrinol. 2010;26(1):58-62.